Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Andreas M Schmitt, Lucy Dumas & James Larkin. (2022) Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. Expert Review of Anticancer Therapy 22:1, pages 17-25.
Read now
Read now
Sadra Behrouzieh, Fateme Sheida & Nima Rezaei. (2021) Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. Expert Review of Anticancer Therapy 21:12, pages 1355-1370.
Read now
Read now
Aikaterini Katsandris, Dimitrios C. Ziogas, Maria Kontouri, Stavroula Staikoglou & Helen Gogas. (2021) Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen. Expert Review of Precision Medicine and Drug Development 6:6, pages 349-360.
Read now
Read now
Fan Xiong, Jing Gong & Qi Wang. (2020) Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report. OncoTargets and Therapy 13, pages 6385-6391.
Read now
Read now
Claudia Trojaniello, Maria Grazia Vitale, Luigi Scarpato, Assunta Esposito & Paolo A. Ascierto. (2020) Melanoma immunotherapy: strategies to overcome pharmacological resistance. Expert Review of Anticancer Therapy 20:4, pages 289-304.
Read now
Read now
Dimitrios C. Ziogas, Frosso Konstantinou, Spyros Bouros & Helen Gogas. (2020) Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. Expert Review of Anticancer Therapy 20:1, pages 53-62.
Read now
Read now
Drew J. Schwartz, Olivia N. Rebeck & Gautam Dantas. (2019) Complex interactions between the microbiome and cancer immune therapy. Critical Reviews in Clinical Laboratory Sciences 56:8, pages 567-585.
Read now
Read now
Ger T. Rijkers, S. Quirine Andriessen & Frans J. van Overveld. (2019) Death and the Miser: microbiota regulate the outcome of checkpoint inhibition immunotherapy. Expert Review of Anticancer Therapy 19:10, pages 831-834.
Read now
Read now
Taku Fujimura, Takanori Hidaka, Yumi Kambayashi & Setsuya Aiba. (2019) BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. Expert Opinion on Investigational Drugs 28:2, pages 143-148.
Read now
Read now
Peng Yue, Taylor Harper, Silvia M. Bacot, Monica Chowdhury, Shiowjen Lee, Adovi Akue, Mark A. Kukuruga, Tao Wang & Gerald M. Feldman. (2019) BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways. OncoImmunology 8:1.
Read now
Read now
Jinhua Zhang, Kun Song, Jun Wang, Yanan Li, Shuangqing Liu, Chengliang Dai, Lieping Chen, Shengdian Wang & Zhihai Qin. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. OncoImmunology 7:4.
Read now
Read now
Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell & Lorenzo Galluzzi. (2017) Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology 6:12.
Read now
Read now
Paola Queirolo & Francesco Spagnolo. (2017) Binimetinib for the treatment of NRAS-mutant melanoma. Expert Review of Anticancer Therapy 17:11, pages 985-990.
Read now
Read now
Articles from other publishers (56)
Zhuo Zhang, Duoli Zhang, Fang Wang, Jiao Liu, Xian Jiang, Songyot Anuchapreeda, Singkome Tima, Zhangang Xiao & Suwit Duangmano. (2023) CD3ζ as a novel predictive biomarker of PD-1 inhibitor resistance in melanoma. Molecular and Cellular Probes 72, pages 101925.
Crossref
Crossref
Maximilian Haist, Henner Stege, Michael Kuske, Julia Bauer, Annika Klumpp, Stephan Grabbe & Matthias Bros. (2023) Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?. Cancer and Metastasis Reviews 42:2, pages 481-505.
Crossref
Crossref
Disha Rao, Ruben Lacroix, Alex Rooker, Tainá Gomes, Johanna A. Stunnenberg, Mesele Valenti, Petros Dimitriadis, Chun-Pu Lin, Beaunelle de Bruijn, Oscar Krijgsman, Maarten A. Ligtenberg, Daniel S. Peeper & Christian U. Blank. (2022) MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance. Melanoma Research 33:1, pages 12-26.
Crossref
Crossref
Signe Caksa, Usman Baqai & Andrew E. Aplin. (2022) The future of targeted kinase inhibitors in melanoma. Pharmacology & Therapeutics 239, pages 108200.
Crossref
Crossref
Marta Morante, Atanasio Pandiella, Piero Crespo & Ana Herrero. (2022) Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. Biomolecules 12:11, pages 1562.
Crossref
Crossref
Mora Guardamagna, Miguel-Angel Berciano-Guerrero, Beatriz Villaescusa-González, Elisabeth Perez-Ruiz, Javier Oliver, Rocío Lavado-Valenzuela, Antonio Rueda-Dominguez, Isabel Barragán & María Isabel Queipo-Ortuño. (2022) Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition. International Journal of Molecular Sciences 23:19, pages 11990.
Crossref
Crossref
Yiqun Zhang, Shijie Lan & Di Wu. (2022) Advanced Acral Melanoma Therapies: Current Status and Future Directions. Current Treatment Options in Oncology 23:10, pages 1405-1427.
Crossref
Crossref
Hardeep Singh Tuli, Katrin Sak, Ashif Iqubal, Renuka Choudhary, Shubham Adhikary, Ginpreet Kaur, Pawan Kumar & Vivek Kumar Garg. (2022) Recent Advances in Immunotherapy for the Treatment of Malignant Melanoma. Current Pharmaceutical Design 28:29, pages 2363-2374.
Crossref
Crossref
Julia R. Dixon-Douglas, Riyaben P. Patel, Pretashini M. Somasundram & Grant A. McArthur. (2022) Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies. Current Oncology Reports 24:8, pages 1071-1079.
Crossref
Crossref
Thomas Yul Avery, Natalie Köhler, Robert Zeiser, Tilman Brummer & Dietrich Alexander Ruess. (2022) Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. Frontiers in Oncology 12.
Crossref
Crossref
Zhizhu Zhang, Ann Richmond & Chi Yan. (2022) Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer. International Journal of Molecular Sciences 23:13, pages 7353.
Crossref
Crossref
Taku Fujimura. (2022) Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers. International Journal of Molecular Sciences 23:7, pages 4044.
Crossref
Crossref
Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan, Avital B Shnerb, Sooraj Mathukkada, Jebrane Bouaoud, Lucas Michon, Ofra Novoplansky, Mai Badarni, Limor Cohen, Ksenia M Yegodayev, Sapir Tzadok, Barak Rotblat, Libor Brezina, Andreas Mock, Andy Karabajakian, Jérôme Fayette, Idan Cohen, Tomer Cooks, Irit Allon, Orr Dimitstein, Benzion Joshua, Dexin Kong, Elena Voronov, Maurizio Scaltriti, Yaron Carmi, Cristina Conde-Lopez, Jochen Hess, Ina Kurth, Luc G T Morris, Pierre Saintigny & Moshe Elkabets. (2022) MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. Journal for ImmunoTherapy of Cancer 10:3, pages e003917.
Crossref
Crossref
Russell G. Witt, Derek J. Erstad & Jennifer A. Wargo. (2022) Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. Therapeutic Advances in Medical Oncology 14, pages 175883592210830.
Crossref
Crossref
Manuela Ferracin, Elisabetta Broseghini & Emi Dika. 2022. MicroRNA in Human Malignancies. MicroRNA in Human Malignancies
339
384
.
Federica Giugliano, Edoardo Crimini, Paolo Tarantino, Paola Zagami, Jacopo Uliano, Chiara Corti, Dario Trapani, Giuseppe Curigliano & Paolo A. Ascierto. (2021) First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. Cancer Treatment Reviews 99, pages 102253.
Crossref
Crossref
Yi-Min Gu, Yue Zhuo, Long-Qi Chen & Yong Yuan. (2021) The Clinical Application of Neoantigens in Esophageal Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Ricardo Alvim, Petrina Georgala, Lucas Nogueira, Alexander Somma, Karan Nagar, Jasmine Thomas, Laura Alvim, Amelia Riegel, Christopher Hughes, Jie Chen, Augusto Reis, Souhil Lebdai, Avigdor Scherz, Steven Zanganeh, Rui Gardner, Kwanghee Kim & Jonathan Coleman. (2021) Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model. Molecules 26:12, pages 3744.
Crossref
Crossref
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, Justin T. Moyers, Michael A. Curran & Hussein A. Tawbi. (2021) Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery 11:6, pages 1368-1397.
Crossref
Crossref
Emily J. Lelliott, Grant A. McArthur, Jane Oliaro & Karen E. Sheppard. (2021) Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Frontiers in Immunology 12.
Crossref
Crossref
Dimitrios C. Ziogas, Frosso Konstantinou, Spyros Bouros, Maria Theochari & Helen Gogas. (2021) Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. American Journal of Clinical Dermatology 22:3, pages 301-314.
Crossref
Crossref
Yang Wang, Bin Lian & Chuan-Liang Cui. (2021) Long-term control of melanoma brain metastases with co-occurring intracranial infection and involuntary drug reduction during COVID-19 pandemic: A case report. World Journal of Clinical Cases 9:10, pages 2373-2379.
Crossref
Crossref
Zhiqin Deng, Na Wang, Fujin Ai, Zhigang Wang & Guangyu Zhu. (2020) Nanomaterial‐mediated platinum drug‐based combinatorial cancer therapy. VIEW 2:1.
Crossref
Crossref
Liming Yu, Fan Peng, Xue Dong, Ying Chen, Dongdong Sun, Shuai Jiang & Chao Deng. (2020) Sex-Determining Region Y Chromosome-Related High-Mobility-Group Box 10 in Cancer: A Potential Therapeutic Target. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Robert Ballotti, Yann Cheli & Corine Bertolotto. (2020) The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?. Molecular Cancer 19:1.
Crossref
Crossref
Shan He, Jinhua Xu & Jinfeng Wu. (2020) The emerging role of co-stimulatory molecules and their agonistic mAb-based combination therapies in melanoma. International Immunopharmacology 89, pages 107097.
Crossref
Crossref
Reinhard Dummer, Paolo A. Ascierto, Paul Nathan, Caroline Robert & Dirk Schadendorf. (2020) Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma. JAMA Oncology 6:12, pages 1957.
Crossref
Crossref
Baohong Luo, Yikang Zhan, Minqi Luo, Huimin Dong, Jun Liu, Yingtong Lin, Junsong Zhang, Guanwen Wang, Els Verhoeyen, Yiwen Zhang & Hui Zhang. (2020) Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration. Cell Death & Disease 11:11.
Crossref
Crossref
Aleksandra Simiczyjew, Ewelina Dratkiewicz, Justyna Mazurkiewicz, Marcin Ziętek, Rafał Matkowski & Dorota Nowak. (2020) The Influence of Tumor Microenvironment on Immune Escape of Melanoma. International Journal of Molecular Sciences 21:21, pages 8359.
Crossref
Crossref
Ilaria Proietti, Nevena Skroza, Simone Michelini, Alessandra Mambrin, Veronica Balduzzi, Nicoletta Bernardini, Anna Marchesiello, Ersilia Tolino, Salvatore Volpe, Patrizia Maddalena, Marco Di Fraia, Giorgio Mangino, Giovanna Romeo & Concetta Potenza. (2020) BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers 12:7, pages 1823.
Crossref
Crossref
Young-Ae Choi, Soyoung Lee, Jin Kyeong Choi, Byeong-Cheol Kang, Min-Jong Kim, Hima Dhakal, Taeg Kyu Kwon, Dongwoo Khang & Sang-Hyun Kim. (2020) The suppressive effect of dabrafenib, a therapeutic agent for metastatic melanoma, in IgE-mediated allergic inflammation. International Immunopharmacology 83, pages 106398.
Crossref
Crossref
Yonghyo Kim, Jeovanis Gil, Indira Pla, Aniel Sanchez, Lazaro Hiram Betancourt, Boram Lee, Roger Appelqvist, Christian Ingvar, Lotta Lundgren, Håkan Olsson, Bo Baldetorp, Ho Jeong Kwon, Henriett Oskolás, Melinda Rezeli, Viktoria Doma, Sarolta Kárpáti, A. Marcell Szasz, István Balázs Németh, Johan Malm & György Marko-Varga. (2020) Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Cancers 12:3, pages 767.
Crossref
Crossref
Shuling Zhang, Xueli Bai & Fengping Shan. (2020) The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer. International Immunopharmacology 80, pages 106247.
Crossref
Crossref
Francesca Varrone & Emilia Caputo. (2020) The miRNAs Role in Melanoma and in Its Resistance to Therapy. International Journal of Molecular Sciences 21:3, pages 878.
Crossref
Crossref
Laura Croce, Francesca Coperchini, Flavia Magri, Luca Chiovato & Mario Rotondi. (2019) The multifaceted anti-cancer effects of BRAF-inhibitors. Oncotarget 10:61, pages 6623-6640.
Crossref
Crossref
Taku Fujimura, Yasuhiro Fujisawa, Yumi Kambayashi & Setsuya Aiba. (2019) Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. Cancers 11:9, pages 1342.
Crossref
Crossref
Hongxing Shen, Eddy Shih-Hsin Yang, Marty Conry, John Fiveash, Carlo Contreras, James A. Bonner & Lewis Zhichang Shi. (2019) Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes & Diseases 6:3, pages 232-246.
Crossref
Crossref
Antoni Ribas, Donald Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H. Miller, Matteo S. Carlino, Rosalie Fisher, Georgina V. Long, F. Stephen Hodi, Jennifer Tsoi, Catherine S. Grasso, Bijoyesh Mookerjee, Qing Zhao, Razi Ghori, Blanca Homet Moreno, Nageatte Ibrahim & Omid Hamid. (2019) Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nature Medicine 25:6, pages 936-940.
Crossref
Crossref
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar-Sela, Felix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno & Antoni Ribas. (2019) Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine 25:6, pages 941-946.
Crossref
Crossref
Chune Yu, Xiaowei Liu, Jiqiao Yang, Min Zhang, Hongyu Jin, Xuelei Ma & Hubing Shi. (2019) Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Frontiers in Immunology 10.
Crossref
Crossref
Tessa Knox, Eva Sahakian, Debarati Banik, Melissa Hadley, Erica Palmer, Satish Noonepalle, Jennifer Kim, John Powers, Maria Gracia-Hernandez, Vasco Oliveira, Fengdong Cheng, Jie Chen, Cyril Barinka, Javier Pinilla-Ibarz, Norman H. Lee, Alan Kozikowski & Alejandro Villagra. (2019) Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Scientific Reports 9:1.
Crossref
Crossref
Jian Li, Xiao-Hong Zhang, Song-Hua Bei & Li Feng. (2019) PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives. World Journal of Meta-Analysis 7:3, pages 101-109.
Crossref
Crossref
Meredith S. Pelster & Rodabe N. Amaria. (2019) Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Therapeutic Advances in Medical Oncology 11, pages 175883591983082.
Crossref
Crossref
Simran S. Sabharwal, David B. Rosen, Jeff Grein, Dana Tedesco, Barbara Joyce-Shaikh, Roanna Ueda, Marie Semana, Michele Bauer, Kathy Bang, Christopher Stevenson, Daniel J. Cua & Luis A. Zúñiga. (2018) GITR Agonism Enhances Cellular Metabolism to Support CD8+ T-cell Proliferation and Effector Cytokine Production in a Mouse Tumor Model. Cancer Immunology Research 6:10, pages 1199-1211.
Crossref
Crossref
Michelle N. Wykes & Sharon R. Lewin. (2017) Immune checkpoint blockade in infectious diseases. Nature Reviews Immunology 18:2, pages 91-104.
Crossref
Crossref
Xianda Zhao & Subbaya Subramanian. (2018) Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy. Pharmacology & Therapeutics 181, pages 76-84.
Crossref
Crossref
Davide Bedognetti, Jessica Roelands, Julie Decock, Ena Wang & Wouter Hendrickx. (2017) The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. Emerging Topics in Life Sciences 1:5, pages 429-445.
Crossref
Crossref
Yo-Ting TsaiAparna LakshmananAmy LehmanBonnie K. Harrington, Fabienne McClanahan LucasMinh TranEllen J. SassMeixiao LongAlan D. Flechtner, Florinda Jaynes, Krista La Perle, Vincenzo CoppolaGerard Lozanski, Natarajan Muthusamy, John C. Byrd, Michael R. GreverDavid M. Lucas. (2017) BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia. Blood Advances 1:24, pages 2147-2160.
Crossref
Crossref
Xiaoyan Liu, Qing Zhou, Yan Xu, Minjiang Chen, Jing Zhao & Mengzhao Wang. (2017) Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?. Oncotarget 8:49, pages 86969-86984.
Crossref
Crossref
Sathana Dushyanthen, Zhi Ling Teo, Franco Caramia, Peter Savas, Christopher P. Mintoff, Balaji Virassamy, Melissa A. Henderson, Stephen J. Luen, Mariam Mansour, Michael H. Kershaw, Joseph A. Trapani, Paul J. Neeson, Roberto Salgado, Grant A. McArthur, Justin M. Balko, Paul A. Beavis, Phillip K. Darcy & Sherene Loi. (2017) Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nature Communications 8:1.
Crossref
Crossref
Bhargavi Pulluri, Abhijeet Kumar, Montaser Shaheen, Joanne Jeter & Srinath Sundararajan. (2017) Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pharmacological Research 123, pages 95-102.
Crossref
Crossref
Changlin Zhang, Chen Song, Tianze Liu, Ranran Tang, Miao Chen, Fan Gao, Binyi Xiao, Ge Qin, Fen Shi, Wenbin Li, Yixin Li, Xiaoyan Fu, Dingbo Shi, Xiangsheng Xiao, Lan Kang, Wenlin Huang, Xiaojun Wu, Bing Tang & Wuguo Deng. (2017) KMT2A promotes melanoma cell growth by targeting hTERT signaling pathway. Cell Death & Disease 8:7, pages e2940-e2940.
Crossref
Crossref
Yang Liu, Pengcheng Cai, Ning Wang, Qianwen Zhang, Fenghua Chen, Liang Shi, Yang Zhang, Lin Wang & Lihua Hu. (2017) Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma. Biochemical and Biophysical Research Communications 484:2, pages 378-384.
Crossref
Crossref
Paola Queirolo & Francesco Spagnolo. (2017) BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. Cancer and Metastasis Reviews 36:1, pages 35-42.
Crossref
Crossref
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A. Wargo & Antoni Ribas. (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168:4, pages 707-723.
Crossref
Crossref
Lidia Robert, Antoni Ribas & Siwen Hu-Lieskovan. (2016) Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. Seminars in Immunology 28:1, pages 73-80.
Crossref
Crossref